BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

2012 in Review: Biocitech SAS Focuses on Collaboration With Regional Players


5/13/2013 10:43:03 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Biocitech, May 13, 2013 – Biocitech, the life sciences technology park based in Paris, France, today announces its annual review of 2012. Biocitech concluded a variety of agreements with regional players throughout 2012, with the aim of creating a support framework ‘par excellence’ for life science SMEs in the Ile de France region of France, including Paris. The agreements are intended to help resident companies on site build their networks and generate business opportunities.

These networking activities ensured that residents could continue to innovate throughout 2012 despite the tough economic climate. Residents recorded the completion of seven preclinical studies during last year and set up three Phase I and two Phase II clinical trials. The number of scientific publications remains significant, with 14 articles published last year. Almost 60 partnership agreements were signed in 2012, compared with 13 in 2011, demonstrating Biocitech’s vitality and the growth of the business activity taking place there.

2012 also saw Biocitech initiate a partnership policy with various players in the Greater Paris region to support residents in developing their businesses. As a result, in July 2012, the technology park concluded a cooperation agreement with AP-HP (the Paris public hospitals system). In this context, sponsors of projects launched by AP-HP can take advantage of easy access to Biocitech premises, while the residents of the technology park can access AP-HP innovations, through technology transfer, joint development and clinical development agreements.

In conjunction with IRD (the French development research institute), the University of Paris 13 and a number of regional and local authorities, Biocitech also helped to found the Bondy Innovation association and Bond'Innov, the association's incubator for innovative projects. This incubator is the only one of its kind in a sensitive urban zone. It provides business founders, particularly in the field of biotechnology, with the opportunity to set up in the Seine-Saint-Denis area; giving them access to skills and resources to launch and start developing their business. Bond'Innov and Biocitech are already lending their support to three biotechnology initiatives:

• Regulaxis, which produces synthetic molecules that inhibit or accelerate growth hormones for diagnostic and therapeutic applications

• Biochoros, which is working on a process to modify the properties of regulatory peptides implicated in cellular signals.

• Selkis, which develops anti-mosquito products for cutaneous application using a new active molecule derived from natural sources.

Finally, Biotech and the CCIP (Paris Chamber of Commerce and Industry) signed a service agreement with a two-fold objective. For the CCIP, this means providing economic information and industrial property monitoring services. The agreement will also see the creation of the Netbiotech network, a grouping of Biocitech park businesses. Netbiotech members will meet several times a year to share best practice, with support from the CCIP.

The Biocitech technology park is highly experienced in providing life science SMEs with tailored business accommodation that can grow with their needs, in combination with services to accelerate the growth of their business. Biocitech offers entrepreneurs a choice of premises to suit their business from start-up to maturity, combining office space with industrial standard laboratories over a floor area of 12 to 5,000 square meters. The businesses on site employ between 1 and 150 staff. The park is the only site in the Ile de France region of France to comply with ICPE regulations (industrial, commercial and agricultural operations subject to particular regulation and environmental protection measures).

“We were keen to set up a dynamic regional network last year. We signed agreements with a number of key partners in the Paris area to support resident companies in their economic development,” said Jean-Francois Boussard, chairman of Biocitech. “These agreements cover different aspects of companies' lifecycles, from start-up to market launch of their products, via financing. In 2013, we plan to introduce private and public investors to the unique features and drive of our resident companies, in order to help them grow their capital.”

About Biocitech

Biocitech is a technology park dedicated to life sciences and the environment. It offers resident companies on-site support from inception to maturity. It provides a range of services that are specifically designed for firms in the sectors of biotechnology, biopharmaceuticals, fine chemicals, medical and in vitro diagnostics and medical devices. Biocitech is the only science and technology park in the Paris area that is ICPE certified and that offers a comprehensive and flexible range of services that include technical buildings, multi-technical services and support services. ICPE certification provides entrepreneurs with secure premises of a high technological standard that are perfectly adapted to their development. The unique combination gives firms the benefit of specialized resources that cost less because they are pooled. Biocitech is located close to Raymond Queneau Paris subway station, and is only 20 minutes from Charles de Gaulle airport.

The park is market-oriented and the great majority of its residents generate revenues from the sale of products or services. Furthermore, the firms installed at Biocitech complement one another, thus generating strong synergies and numerous collaborations.

Along with other organizations in the Paris area, Biocitech is a key element in the Medicen Paris Region network, the Greater Paris region’s world-class competitiveness hub for health and new therapies.

For further information, go to: http://www.biocitech.com

Mark Tidmarsh

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

mark@ala.com

Follow us on Twitter: https://twitter.com/ALA_Group

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND

Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE

Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->